O
Otto Visser
Researcher at VU University Medical Center
Publications - 264
Citations - 18801
Otto Visser is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Population & Cancer. The author has an hindex of 53, co-authored 240 publications receiving 14262 citations. Previous affiliations of Otto Visser include Utrecht University & University Medical Center Groningen.
Papers
More filters
Journal ArticleDOI
Management of recurrent rectal cancer: A population based study in greater Amsterdam
Roel Bakx,Otto Visser,Judith Josso,Sybren L. Meijer,J. Frederik M. Slors,J. Jan B. van Lanschot +5 more
TL;DR: Although treatment options and survival are limited in case of recurrent rectal cancer after radical local resection obtained with TME, patients can benefit from additional treatment, especially if a radical resection is feasible.
Journal ArticleDOI
Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study
Marc Maynadié,Roberta De Angelis,Rafael Marcos-Gragera,Otto Visser,Claudia Allemani,Carmen Tereanu,Riccardo Capocaccia,Adriano Giacomin,Jean-Michel Lutz,Carmen Martos,Risto Sankila,Tom Børge Johannesen,Arianna Simonetti,Milena Sant +13 more
TL;DR: This is the first paper to present large-scale, European survival data for patients with myeloid malignancies using prognosis-based groupings of entities defined by the third revision of the International Classification of Diseases for Oncology/World Health Organization classifications.
Journal ArticleDOI
Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study.
Karlijn de Joode,Daphne W. Dumoulin,Jolien Tol,Hans M. Westgeest,Laurens V. Beerepoot,Franchette W P J van den Berkmortel,Pim G N J Mutsaers,Nico G.J. van Diemen,Otto Visser,Esther Oomen-de Hoop,Haiko J. Bloemendal,Hanneke W. M. van Laarhoven,Lizza E.L. Hendriks,John B. A. G. Haanen,Elisabeth G.E. de Vries,Anne-Marie C. Dingemans,Astrid A M van der Veldt,C. J. van Loenhout,C. H. van der Leest,A. Becker-Commissaris,Jessica S.W. Borgers,F. Terhegggen,B. van den Borne,L. J. C. van Warmerdam,L. van Leeuwen,F. S. van der Meer,M. A. Tiemessen,D. M. van Diepen,Y. Klaver,A. P. Hamberg,E. J. Libourel,L. Strobbe,M. Cloos,E. J. Geraedts,J. C. Drooger,R. Heller,J.W.B. de Groot,J. A. Stigt,V. J.A.A. Nuij,C. C.M. Pitz,M. Slingerland,F. J. Borm,B. C.M. Haberkorn,S. C.van t. Westeinde,Mieke J. Aarts,J. W. G. van Putten,M. Youssef,G. A. Cirkel,G. J.M. Herder,C. R. van Rooijen,E. Citgez,N. P. Barlo,B. M.J. Scholtes,Rutger H. T. Koornstra,N. J.M. Claessens,L. M. Faber,C. H. Rikers,R. A.W. van de Wetering,G. L. Veurink,B. W. Bouter,I. Houtenbos,M. P.L. Bard,K. H. Herbschleb,E. A. Kastelijn,P. Brocken,G. Douma,Mathilde Jalving,T. J.N. Hiltermann,O. C.J. Schuurbiers-Siebers,Karijn P M Suijkerbuijk,A. S.R. van Lindert,A.J. van de Wouw,V. E.M. van den Boogaart,S. D. Bakker,E. Looysen,A. L. Peerdeman,W. K. de Jong,E. J.M. Siemerink,A. J. Staal,B. Franken,W. H. van Geffen,G. P. Bootsma +81 more
TL;DR: The findings in this registry indicate that patients with a haematological malignancy or lung cancer have an increased risk of a worse outcome of COVID-19, whereas treatment adjustments and prioritizing vaccination, when available, should also be considered.
Journal ArticleDOI
Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012
A.G. Dinmohamed,Otto Visser,Y. van Norden,Nicole M. A. Blijlevens,Jan J. Cornelissen,Gerwin Huls,Peter C. Huijgens,Pieter Sonneveld,A.A. van de Loosdrecht,Gert J. Ossenkoppele,Bob Löwenberg,Mojca Jongen-Lavrencic +11 more
TL;DR: As survival remained poor for older AML patients over the last two decades, clinical trials and active participation in those trials, are warranted that explore innovative treatment strategies for this elderly population.
Journal ArticleDOI
Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities
Silvia Stacchiotti,Anna Maria Frezza,Jean-Yves Blay,Elizabeth H. Baldini,Sylvie Bonvalot,Judith V.M.G. Bovée,Dario Callegaro,Paolo G. Casali,Ru Ru Chun ju Chiang,George D. Demetri,Elisabeth G. Demicco,Jayesh Desai,Mikael Eriksson,Hans Gelderblom,Suzanne George,Mrinal M. Gounder,Mrinal M. Gounder,Alessandro Gronchi,Abha A. Gupta,Rick L. Haas,Rick L. Haas,Andrea Hayes-Jardon,Peter Hohenberger,Kevin B. Jones,Robin L. Jones,Bernd Kasper,Akira Kawai,David G. Kirsch,Eugene S. Kleinerman,Axel Le Cesne,Jiwon Lim,María Dolores López,Roberta Maestro,Rafael Marcos-Gragera,Javier Martin Broto,Tomohiro Matsuda,Olivier Mir,Shreyaskumar Patel,Chandrajit P. Raut,Chandrajit P. Raut,Albiruni Ryan Abdul Razak,Damon R. Reed,Piotr Rutkowski,Roberta Sanfilippo,Marta Sbaraglia,Inga-Marie Schaefer,Dirk C. Strauss,Kirsten Sundby Hall,William D. Tap,William D. Tap,David Thomas,Winette T. A. van der Graaf,Winan J. van Houdt,Otto Visser,Margaret von Mehren,Andrew J. Wagner,Breelyn A. Wilky,Young-Joo Won,Christopher D.M. Fletcher,Angelo Paolo Dei Tos,Annalisa Trama +60 more
TL;DR: In this article, a list of ultra-rare sarcomas was defined as those with an incidence of ≤ 1 per 1,000,000 to include those entities whose rarity renders them extremely difficult to conduct well powered, prospective clinical studies.